Three Lakes Foundation has recently announced that it is partnering with Lung Foundation Australia, the Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) and an Australian philanthropist with a personal connection to the rare disease.
A three-dose regimen of Plasmodium falciparum sporozoites under chemoprophylaxis (PfSPZ-CVac) was shown to be safe, well tolerated and highly effective in a Phase II trial.